Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 5, 2008, Pages 373-378

  Abe, Shintaro ^a   Narita, Ryoichi ^a   Matsuhashi, Toru ^a   Oto, Takeshi ^a   Tabaru, Akinari ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Chronic hepatitis C; Interferon 2b; Ribavirin; Soluble interleukin 2 receptor; Sustained virologic response

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RIBAVIRIN; RNA, VIRAL; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 42149158878     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f43aae     Document Type: Article

References (48)

1. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, et al. Predictors of sustained response to α interferon therapy in chronic hepatitis C. J Hepatol 1998; 29:214-223.
2. Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Remire J, Metreau JM, et al. Factors affecting treatment responses to interferon-α in chronic hepatitis C. J Infect Dis 1996; 174:1-7.
3. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, et al. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon α therapy in patients with chronic hepatitis C. J Med Virol 1998; 54:256-264.
4. Thevenot T, Rigimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Metaanalysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepatol 2001; 8:48-62.
5. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30:787-793.
6. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon α2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26:1640.
7. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30:595-601.
8. + T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996; 74:583-588.
9. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995; 21:632-638.
10. Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160:1479-1488.
11. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-1512.
12. He XS, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999; 96:5692-5697.
13. + T-cell response in acute hepatitis C. Gastroenterology 1999; 117:180-185.
14. Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001; 121:646-656.
15. Löhr HF, Gerken G, Roth M, Weyer S, Schlaak JF, Meyer zum Buschenfelde KH. The cellular immune responses induced in the follow-up of interferon-α treated patients with chronic hepatitis C may determine the therapy outcome. J Hepatol 1998; 29:524-532.
16. Katayama K, Kasahara A, Sasaki Y, Kashiwagi T, Naito M, Masuzawa M, et al. Immunological response to interferon-γ priming prior to interferon-α treatment in refractory chronic hepatitis C in relation to viral clearance. J Viral Hepatol 2001; 8:180-185.
17. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19:157-169.
18. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135:3172-3177.
19. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
20. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321-1324.
21. Lai KN, Leung JC, Li PK, Lui SF. Cytokine production by peripheral blood mononuclear cells in IgA nephropathy. Clin Exp Immunol 1991; 85:240-245.
22. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
24. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990; 113:619-627.
25. Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137:3841-3844.
26. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-1007.
27. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706-714.
28. Cramp ME, Carucci P, Rossol S, Choksi S, Maertens G, Williams R, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999; 44:424-429.
29. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104:580-587.
30. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, et al. Effects of interferon treatment on the anti-viral T-cell response in hepatitis C virus genotype 1b- and 2c-infected patients. Hepatology 1997; 26:792-797.
31. Lasarte JJ, Garcia-Granero M, Lopez A, Casares N, Garcia N, Civeira MP, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998; 28:815-822.
32. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346-355.
33. + T cells and monocytes. Blood 1996; 87:4731-4736.
34. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy in interferon-α therapy. Science 1998; 282:103-107.
35. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon α plus ribavirin and intravenous twice-daily treatment with interferon β. Hepatology 2001; 84:377-384.
36. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon α-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457-1462.
37. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 1994; 19:280-285.
38. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, et al. Prolonged treatment (2 years) with different doses (3 vs. 6MU) of interferon α-2b for chronic hepatitis type C. Results of a multicenter randomized trial. J Hepatol 1997; 27:56-62.
39. Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, et al. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 2003; 38:158-163.
40. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
41. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
42. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-87.
43. Abe S, Narita R, Oto T, Tabaru A, Otsuki M. Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C. J Gastroenterol Hepatol 2006; 21:308-312.
44. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26:961-966.
45. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
46. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
47. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
48. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon α-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-218.